Jonathan Lewis, M.D., Ph.D.
Chief Executive Officer and Executive Chairman

Dr. Lewis is Chief Executive Officer and a Director, serving in these capacities since January 2004. Additionally, Dr. Lewis has been Chief Medical Officer since June 2008. From July 1994 until June 2001, Dr. Lewis served as Professor of Surgery and Medicine at Memorial Sloan-Kettering Cancer Center. He has been actively involved in leading translational and clinical research in cancer, and is widely recognized by patient advocacy groups. He has received numerous honors and awards in medicine and science, including the ASCO Young Investigator Award, the Yale University Ohse Award, and the Royal College of Surgeons Trubshaw Medal. He served as Chief Medical Officer and Chairman of the Medical Board at Antigenics, Inc. from June 2000 until November 2003. He serves as a Director on the Board of Delcath Systems, Inc. (Nasdaq:DCTH) and of POPPA (the Police Organization Providing Peer Assistance) of the New York Police Department (NYPD). He also serves on the Medical Advisory Board of the Sarcoma Foundation of America.

Dick Bagley
President and Chief Operating Officer, Director and Treasurer

Mr. Bagley is President and Chief Operating Officer and a Director and has served in this capacity since July 2004. Additionally, Mr. Bagley has been Chief Financial Officer and Treasurer since March 2005. Mr. Bagley initiated a career in pharmaceuticals in 1968 with Smith Kline and French Laboratories, leaving in 1985 after launching Tagamet® in the U.S. as Vice President for Pharmaceutical Product Management and serving as President in the over-the-counter/consumer group. From 1985-1990, Mr. Bagley served in several capacities at Squibb Corporation including as President of E. R. Squibb & Sons, U.S. in 1988 and 1989. He subsequently worked in the biotechnology industry as Director, Chief Executive Officer and President of ImmuLogic Pharmaceutical Corporation from 1990 to 1994, as Director, Chief Executive Officer and Chairman of ProScript, Inc. from 1994 to 1998, as Director, President and Chief Executive Officer of AltaRex Corp. from 1998 to May 2003, and thereafter as a part time consultant and senior advisor.

Barbara Wallner, Ph.D.
Chief Technology Officer

Dr. Wallner is Chief Technology Officer having joined the Company in 2006. During her 26 years of industry experience, Dr. Wallner has authored more than 150 issued patents and patent applications worldwide. While with Biogen, she identified Amevive®, which obtained market approval. As a Co-Founder of Point Therapeutics, she successfully built and financed the company and led its R&D programs. Dr. Wallner has also held leadership positions with ImmuLogic and BioTransplant. She serves on the Board of Associates of the Whitehead Institute, MIT.

Barry Jones, Ph.D.
Senior Vice President, Preclinical Operations

Dr. Jones is Senior Vice President of Preclinical Operations and has served in this capacity since February 2008. During his 15 years of industry experience and 10 years of academic research, Dr. Jones has authored over 50 publications and 9 patents and patent applications in the United States. Previously he was at Point Therapeutics where he was the leader of the preclinical team responsible for integrating research programs with business goals and translating research discoveries into clinical programs. Before joining Point Therapeutics in 1997, Dr. Jones was with Procept, Inc. as Director of Immunology. His research has been published and presented at international scientific meetings. Dr. Jones is also a member of the American Association of Cancer Research.

Bob Morgan, J.D.
Senior Vice President, Regulatory Affairs, Quality, and Clinical Development

Mr. Morgan is Senior Vice President, Regulatory Affairs, Quality, and Clinical Development and has served in that capacity since June 2008. Previously, Mr. Morgan was the Vice President, Regulatory Affairs and Quality, and Contract Counsel since January 2006. During his career he has submitted and maintained multiple IND, NDA and International regulatory filings and has been the team leader for multinational clinical studies. He also filed the first electronic IND application accepted by the FDA in the new international standard Common Technical Document format. Mr. Morgan has held positions in medical research and clinical/regulatory settings with EPIX Pharmaceuticals, DuPont, Genzyme, PAREXEL and Theseus Imaging before joining ZIOPHARM. He is also a member of the Massachusetts Bar.

John Amedio, Ph.D.
Vice President, Manufacturing & Process Development

Dr. Amedio is Vice President, Manufacturing & Process Development, serving in this capacity since 2006. Dr. Amedio has seventeen years of experience in major and start-up pharmaceutical companies. He has extensive experience in all aspects of Chemistry, Manufacturing and Controls (CMC), including regulatory agency document preparation, active pharmaceutical ingredient synthesis, drug product pre-formulation and formulation, analytical methods development and the preparation of clinical trial materials. Most recently Dr. Amedio was Executive Director, Analytical and Chemical R&D, EPIX Pharmaceuticals, Cambridge, MA. Before joining EPIX in 1995, Dr. Amedio was with Sandoz Research Institute (currently Novartis Pharmaceuticals), East Hanover, New Jersey, as a Unit Leader in the Chemical Research and Development department.

Steve Bloom
Vice President, Business Development

Mr. Bloom is Vice President of Business Development and has served in this capacity since March 2008. He has over 20 years of international experience in licensing, competitive product evaluation, marketing, and business development including brand management, product management, market research and public affairs/legislative advocacy. Mr. Bloom has held increasing levels of responsibility at Eli Lilly and Company, Inflexxion Inc., PHARMetrics, Inc., and PAREXEL. At Eli Lilly, Mr. Bloom developed and executed the brand strategy for Prozac®. During his tenure at PAREXEL, he reorganized the sales and delivery team and streamlined the marketing planning and strategy to focus on core capabilities. Mr. Bloom has proven his leadership ability in start-up and high-growth companies serving the biotech and healthcare technology space.

Jan Stevens, RN
Vice President, Clinical Operations

Ms. Stevens is Vice President, Clinical Operations, serving in this capacity since June 2008. Previously, Ms. Stevens was the Senior Director of Clinical Operations since November 2005. Ms. Stevens was responsible for building the clinical organization at ZIOPHARM, and has 20 years of experience in clinical research and development programs at various institutions and in oncology nursing. Prior to ZIOPHARM, Ms. Stevens was Associate Director of Clinical Affairs at Therion Biologics in Cambridge, MA where she brought lead program Panvac-VF from initial IND filing through a phase III clinical trial under an SPA in less than three years. Before joining Therion, Ms. Stevens has held increasing levels of responsibility at Antigenics, CareStat, Inc. and Harvard University Medical Services.